So, there is an urgent need to restore adrenal inhibition in obese individuals.<h4>Evidence acquisition</h4>We searched PubMed articles and included them if relevant.<h4>Conclusions</h4>Individuals with obesity and high levels of adipose insulin resistance may benefit from CRF1/ACTH inhibitors, reducing ACTH secretion or its action. Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.